Shots:
- Galderma announced the initiation of two P‑II clinical studies evaluating the efficacy and safety of nemolizumab in pts with SSc and CPUO
- Patient enrollment for both studies is planned to start in H2’25, with expected completion in 2028 for SSc and in 2026 (US) for CPUO
- Nemolizumab is a mAb targeting the IL‑31 receptor alpha, and is already US FDA approved for prurigo nodularis (Aug 2024) in adults and for moderate‑to‑severe atopic dermatitis in ≥12yrs. pts (Dec 2024), and is authorized in multiple markets worldwide
Ref: Galderma | Image: Galderma | Press Release
Related News:- Libertas Bio Licenses Gusacitinib to Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
